Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 60, Issue 5, Pages 587-591Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.118.220806
Keywords
bioconjugation; immuno-PET; antibodies; protein ligation; enzymes; photoradiochemistry
Funding
- European Union's Horizon 2020 research and innovation programme/from the European Research Council [676904]
- Swiss National Science Foundation (SNSF) [PP00P2_163683]
- Swiss Cancer League (Krebsliga Schweiz) [KLS-4257-08-2017]
- University of Zurich (UZH)
Ask authors/readers for more resources
The use of radiolabeled antibodies, immunoglobulin fragments, and other proteins are an increasingly important sector of research for diagnostic imaging and targeted radiotherapy in nuclear medicine. As with all radiopharmaceuticals, efficient radiochemistry is a prerequisite to clinical translation. For proteins, variations in the primary amino acid sequence, the secondary structures, and tertiary folds, as well as differences in the size, charge, polarity, lipophilicity, and the presence of posttranslational modifications, add complexity to the system. The choice of radionuclide or chelate, and its impact on the thermodynamic, kinetic, and metabolic stability of a radiotracer, has attracted much attention but the chemistry by which the radionuclide is conjugated to the protein scaffold is of equal importance. Recently, a wealth of creative advances in protein ligation methods based on chemical, photochemical, and enzyme-mediated processes has emerged. As radiochemists explore alternative bioconjugation strategies, this article considers their potential impact on radiotracer design.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available